Clinical Evaluation of the Phototoxic Potential of Xenaderm Ointment
NCT ID: NCT00644917
Last Updated: 2014-01-13
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
38 participants
INTERVENTIONAL
2008-02-29
2008-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment
NCT00645164
Phototoxicity Test of Dapsone Gel in Healthy Volunteers
NCT02108483
Safety Dermatological Assessment of Topical Use Product Through Dressings Predictive Studies for Evaluation of Photoirritation and Dermal Photosensitivity
NCT02441608
18348-Human Phototoxicity Test
NCT02823483
A Phase I/IIa Study to Investigate the GM-XANTHO in Healthy Volunteers and Atopic Dermatitis Patients
NCT04369846
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Drug
Xenaderm
20mg under Finn chambers
B
Placebo comparator
Placebo
20mg under Finn chambers
C
Subjects serve as own controls.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Xenaderm
20mg under Finn chambers
Placebo
20mg under Finn chambers
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Healthpoint
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Healthpoint, Ltd.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Innes Cargill, PhD
Role: STUDY_DIRECTOR
Healthpoint, Ltd.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
011 101 09 001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.